Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the Rule (LOGYST)

February 14, 2023 updated by: Hospices Civils de Lyon

LOw Grade Serous Ovarian Carcinoma and Uterine Involvement : Should hYSTerectomy be the Rule

Investigators studied a population of 28 low grade serous ovarian carcinoma treated in Hospices civils de Lyon between 2000 and 2022. The primary objective is to determinate the rate of myometrial involvement by the cancer at pathology examination. Then, investigators compared patients with or without myometrial involvement : survival parameters, predictive factors of myometrial involvement (age, CA 125 level, surgery characteristics, pathology characteristics).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

28

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lyon, France, 69000
        • Hospices Civils de Lyon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

All patients treated in hospices Civils de Lyon for a Low grade serous ovarian cancer between January 2000 and May 2022

Description

  • Inclusion Criteria :

    • 18 years old or more
    • low grade serous ovarian cancer (MDACC classification)
    • Grade 1 serous ovarian carcinoma (Silverberg classification)

  • Exclusion Criteria :

    • no sufficient data available
    • grade 2 and 3 serous ovarian carcinoma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Myometrial involvement
Myometrial involvement by cancer metastasis after pathology examination
Other: Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.
Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
No myometrial involvement
Absence of myometrial involvement by cancer metastasis after pathology examination
Other: Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.
Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of myometrial involvement
Time Frame: After pathology examination, average 2 to 3 weeks after cytoreductive surgery
Myometrial involvement after pathology examination
After pathology examination, average 2 to 3 weeks after cytoreductive surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Actual)

June 1, 2022

Study Completion (Actual)

October 10, 2022

Study Registration Dates

First Submitted

February 14, 2023

First Submitted That Met QC Criteria

February 14, 2023

First Posted (Estimate)

February 23, 2023

Study Record Updates

Last Update Posted (Estimate)

February 23, 2023

Last Update Submitted That Met QC Criteria

February 14, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 22-5035
  • 69HCL23_0175 (Other Identifier: HCL)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Serous Ovarian Carcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe